Strategic Blueprint’s bluebird bio BLUE Stock Holding History

Strategic Blueprint’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8	Closed	-$3K	–	504
2021 Q2	$3K	Buy	+8	New	+$3.17K	﹤0.01%	1158

Other funds holding BLUE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Strategic Blueprint's BLUE Position: Q3 2021 in Review

Strategic Blueprint sold out of bluebird bio (BLUE) in Q3 2021, closing a stake of 8 shares — an estimated $3K sold.

Strategic Blueprint first reported a position in BLUE in Q2 2021 and held it in 1 quarter. The position peaked at $3K in Q2 2021. 196 funds tracked by Wall St. Rank hold BLUE as of Q3 2021.

Strategic Blueprint reported no remaining bluebird bio position as of Q3 2021 after selling out during the quarter.
Strategic Blueprint sold 8 bluebird bio shares in Q3 2021, an estimated $3K.
Strategic Blueprint first reported a position in bluebird bio in Q2 2021 and held it in 1 quarter.
Strategic Blueprint's bluebird bio position peaked at $3K in Q2 2021.
196 funds tracked by Wall St. Rank held bluebird bio as of Q3 2021.

Based on Strategic Blueprint's 13F filing for Q3 2021, filed 12 Nov 2021.